Startseite>>Infectious Disease>> Bacterial Diseases>>Avrainvillamide

Avrainvillamide (Synonyms: CJ-17,665)

Katalog-Nr.GC48511

Avrainvillamid ((+)-Avrainvillamid) ist ein natÜrlich vorkommendes Alkaloid mit antiproliferativen Wirkungen, das an das nukleÄre Chaperon Nucleophosmin bindet, ein vorgeschlagenes onkogenes Protein, das in vielen verschiedenen menschlichen Tumoren Überexprimiert wird.

Products are for research use only. Not for human use. We do not sell to patients.

Avrainvillamide Chemische Struktur

Cas No.: 269741-97-1

Größe Preis Lagerbestand Menge
250µg
301,00 $
Auf Lager
1mg
1.020,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Avrainvillamide is a fungal metabolite and monomeric form of stephacidin B that has been found in A. ochraceus.1,2 It is active against S. aureus, S. pyogenes, and E. faecalis (MICs = 12.5, 12.5, and 25 µg/ml, respectively).2 Avrainvillamide inhibits the growth of LNCaP, BT-549, T47D, and MALME-3M cancer cells with GI50 values of 0.24, 0.62, 0.21, and 0.41 µM, respectively.1

1.Wulff, J.E., Herzon, S.B., Siegrist, R., et al.Evidence for the rapid conversion of stephacidin B into the electrophilic monomer avrainvillamide in cell cultureJ. Am. Chem. Soc.129(16)4898-4899(2007) 2.Sugie, Y., Hirai, H., Inagaki, T., et al.A new antibiotic CJ-17,665 from Aspergillus ochraceusJ. Antibiot.54(11)911-916(2001)

Bewertungen

Review for Avrainvillamide

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Avrainvillamide

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.